Lexeo Therapeutics, INC Form 4 insider transactions

Lexeo Therapeutics CEO Richard Nolan Townsend amended a Form 4 filing, correcting the number of shares sold to cover tax obligations on restricted stock units.

Lexeo Therapeutics' Chief Financial Officer, Louis Edward Tamayo, was granted 45,000 Restricted Stock Units and 280,000 stock options, vesting over time.

Lexeo Therapeutics' Chief Technical Officer, Jose Manuel Otero, sold 2,848 shares of common stock to cover tax obligations related to restricted stock units.

Lexeo Therapeutics' Chief Legal Officer, Jenny Robertson, sold 542 shares of common stock to cover tax obligations related to restricted stock units.

Lexeo Therapeutics' Chief Medical Officer, Eric Adler, reported the sale of 608 common shares to cover tax obligations related to restricted stock units.

Lexeo Therapeutics CEO Richard Townsend sold 2,735 shares of common stock to cover tax obligations related to restricted stock units.

Lexeo Therapeutics' Chief Development Officer, Sandi See Tai, sold 382 shares of common stock to cover tax obligations related to restricted stock units.

Lexeo Therapeutics, Inc. Director Tolga Tanguler was granted 14,583 stock options with an exercise price of $4.18, vesting by June 2026.

Lexeo Therapeutics, Inc. Director Timothy Van Hauwermeiren was granted 22,916 stock options with an exercise price of $4.18, vesting on the earlier of June 26, 2026, or the next annual stockholders meeting.

Lexeo Therapeutics, Inc. Director Reinaldo M. Diaz was granted 25,000 stock options with an exercise price of $4.18, aligning his interests with shareholder value.

Lexeo Therapeutics, Inc. Director Brenda Cooperstone was granted 25,000 stock options with an exercise price of $4.18, vesting on the earlier of June 26, 2026, or the next annual stockholders meeting.

Lexeo Therapeutics, Inc. Director Paula H. Cholmondeley was granted 25,000 stock options with an exercise price of $4.18, vesting on the earlier of June 26, 2026, or the next annual stockholders meeting.

Steven Altschuler, a Director at Lexeo Therapeutics, Inc., was granted 25,000 stock options with an exercise price of $4.18 per share, vesting on the earlier of June 26, 2026, or the next annual stockholders meeting.

Lexeo Therapeutics, Inc. director Mette Kirstine Agger was granted 25,000 stock options with an exercise price of $4.18, vesting on the earlier of June 26, 2026, or the next annual stockholders meeting.

Lexeo Therapeutics CEO Richard Nolan Townsend sold 1,074 shares of common stock on May 16, 2025, to cover tax obligations related to the release of restricted stock units.

Eric Adler, Chief Medical Officer of Lexeo Therapeutics, sold 585 shares of common stock on May 16, 2025, to cover tax obligations related to the release of restricted stock units.

Jenny Robertson, Chief Legal Officer of Lexeo Therapeutics, sold 521 shares of common stock on May 16, 2025, to cover tax obligations related to the release of restricted stock units.

Sandi See Tai, Chief Development Officer of Lexeo Therapeutics, sold 367 shares of common stock on May 16, 2025, to cover tax obligations related to the release of restricted stock units.

Jose Manuel Otero, Chief Technical Officer of Lexeo Therapeutics, reports acquiring 5,720 shares of common stock through the company's Employee Stock Purchase Plan.

Jenny Robertson, Chief Legal Officer of Lexeo Therapeutics, reports acquiring 5,720 shares of common stock through the company's Employee Stock Purchase Plan.

Sandi See Tai, Chief Development Officer of Lexeo Therapeutics, reports acquiring 5,720 shares of common stock through the company's Employee Stock Purchase Plan.

Richard Nolan Townsend, CEO of Lexeo Therapeutics, reports the acquisition of 2,128 shares of common stock through the company's Employee Stock Purchase Plan.

Lexeo Therapeutics CEO Richard Nolan Townsend sold 4,326 shares of common stock on February 19, 2025, to cover tax obligations related to the release of restricted stock units.

Sandi See Tai, Chief Development Officer of Lexeo Therapeutics, sold 1,486 shares of common stock to cover tax obligations related to the release of restricted stock units.

Eric Adler, Chief Medical Officer of Lexeo Therapeutics, sold 2,359 shares of common stock on February 19, 2025, to cover tax obligations related to the release of restricted stock units.

Jenny Robertson, Chief Legal Officer of Lexeo Therapeutics, sold 2,101 shares of common stock on February 19, 2025, to cover tax obligations related to the release of restricted stock units.

Chief Financial Officer Kyle Rasbach of Lexeo Therapeutics reports the acquisition of restricted stock units and stock options.

Richard Nolan Townsend, CEO of Lexeo Therapeutics, reports acquisition of shares and stock options.

Jose Manuel Otero, Chief Technical Officer of Lexeo Therapeutics, reports acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.

Jenny Robertson, Chief Legal & Admin Officer of Lexeo Therapeutics, reports acquiring and disposing of common stock and stock options in a transaction dated January 7, 2025.